News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
709,881 Results
Type
Article (40305)
Company Profile (255)
Press Release (669310)
Multimedia
Podcasts (68)
Webinars (15)
Section
Business (204420)
Career Advice (2015)
Deals (35470)
Drug Delivery (99)
Drug Development (81211)
Employer Resources (172)
FDA (16292)
Job Trends (14908)
News (345797)
Policy (32665)
Tag
Academia (2557)
Accelerated approval (14)
Adcomms (24)
Allergies (108)
Alliances (49573)
ALS (126)
Alzheimer's disease (1518)
Antibody-drug conjugate (ADC) (168)
Approvals (16344)
Artificial intelligence (355)
Autoimmune disease (39)
Automation (23)
Bankruptcy (361)
Best Places to Work (11636)
BIOSECURE Act (19)
Biosimilars (136)
Biotechnology (174)
Bladder cancer (111)
Brain cancer (39)
Breast cancer (411)
Cancer (3299)
Cardiovascular disease (269)
Career advice (1689)
Career pathing (32)
CAR-T (205)
CDC (38)
Cell therapy (547)
Cervical cancer (27)
Clinical research (67483)
Collaboration (1181)
Company closure (4)
Compensation (839)
Complete response letters (36)
COVID-19 (2658)
CRISPR (67)
C-suite (475)
Cystic fibrosis (120)
Data (3730)
Decentralized trials (2)
Denatured (22)
Depression (82)
Diabetes (392)
Diagnostics (6491)
Digital health (27)
Diversity (10)
Diversity, equity & inclusion (45)
Drug discovery (163)
Drug pricing (136)
Drug shortages (28)
Duchenne muscular dystrophy (170)
Earnings (88536)
Editorial (44)
Employer branding (21)
Employer resources (148)
Events (114647)
Executive appointments (889)
FDA (18437)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (4)
Frontotemporal dementia (10)
Funding (1049)
Gene editing (147)
Generative AI (25)
Gene therapy (431)
GLP-1 (841)
Government (4573)
Grass and pollen (5)
Guidances (331)
Healthcare (18851)
HIV (42)
Huntington's disease (32)
IgA nephropathy (47)
Immunology and inflammation (186)
Immuno-oncology (14)
Indications (46)
Infectious disease (2851)
Inflammatory bowel disease (162)
Inflation Reduction Act (10)
Influenza (77)
Intellectual property (162)
Interviews (314)
IPO (16604)
IRA (48)
Job creations (3640)
Job search strategy (1424)
Kidney cancer (13)
Labor market (64)
Layoffs (521)
Leadership (22)
Legal (7934)
Liver cancer (83)
Longevity (11)
Lung cancer (475)
Lymphoma (242)
Machine learning (22)
Management (58)
Manufacturing (509)
MASH (110)
Medical device (13560)
Medtech (13577)
Mergers & acquisitions (19671)
Metabolic disorders (954)
Multiple sclerosis (113)
NASH (16)
Neurodegenerative disease (155)
Neuropsychiatric disorders (37)
Neuroscience (2338)
NextGen: Class of 2025 (6516)
Non-profit (4492)
Now hiring (53)
Obesity (463)
Opinion (229)
Ovarian cancer (110)
Pain (138)
Pancreatic cancer (142)
Parkinson's disease (200)
Partnered (24)
Patents (366)
Patient recruitment (260)
Peanut (52)
People (58019)
Pharmaceutical (63)
Pharmacy benefit managers (21)
Phase I (21002)
Phase II (29725)
Phase III (22115)
Pipeline (2409)
Policy (230)
Postmarket research (2564)
Preclinical (8949)
Press Release (64)
Prostate cancer (164)
Psychedelics (39)
Radiopharmaceuticals (255)
Rare diseases (524)
Real estate (5927)
Recruiting (66)
Regulatory (23130)
Reports (51)
Research institute (2336)
Resumes & cover letters (350)
Rett syndrome (11)
RNA editing (11)
RSV (55)
Schizophrenia (108)
Series A (173)
Series B (131)
Service/supplier (11)
Sickle cell disease (70)
Special edition (20)
Spinal muscular atrophy (148)
Sponsored (34)
Startups (3595)
State (2)
Stomach cancer (14)
Supply chain (87)
Tariffs (72)
The Weekly (44)
Vaccines (862)
Venture capital (59)
Weight loss (291)
Women's health (51)
Worklife (17)
Date
Today (86)
Last 7 days (485)
Last 30 days (2208)
Last 365 days (30827)
2025 (21769)
2024 (35216)
2023 (40076)
2022 (51174)
2021 (55710)
2020 (54084)
2019 (46538)
2018 (35018)
2017 (32108)
2016 (31480)
2015 (37554)
2014 (31320)
2013 (26345)
2012 (28572)
2011 (29264)
2010 (27328)
Location
Africa (724)
Alabama (69)
Alaska (7)
Arizona (261)
Arkansas (13)
Asia (38473)
Australia (6273)
California (8568)
Canada (2652)
China (779)
Colorado (358)
Connecticut (367)
Delaware (227)
Europe (82792)
Florida (1277)
Georgia (287)
Hawaii (2)
Idaho (60)
Illinois (681)
India (40)
Indiana (405)
Iowa (17)
Japan (260)
Kansas (116)
Kentucky (31)
Louisiana (16)
Maine (65)
Maryland (1137)
Massachusetts (6263)
Michigan (266)
Minnesota (506)
Mississippi (4)
Missouri (101)
Montana (28)
Nebraska (25)
Nevada (98)
New Hampshire (68)
New Jersey (2338)
New Mexico (28)
New York (2330)
North Carolina (1195)
North Dakota (8)
Northern California (3891)
Ohio (261)
Oklahoma (17)
Oregon (35)
Pennsylvania (1808)
Puerto Rico (17)
Rhode Island (41)
South America (1099)
South Carolina (43)
South Dakota (1)
Southern California (3291)
Tennessee (138)
Texas (1320)
United States (31185)
Utah (254)
Virginia (210)
Washington D.C. (75)
Washington State (712)
West Virginia (4)
Wisconsin (72)
709,881 Results for "nitto denko avecia inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Nitto Acquires Bend Labs, Inc. in the United States
Nitto Denko Corporation (headquarter: Osaka, Japan, President: Hideo Takasaki, hereafter Nitto) (TOKYO:6988) and Bend Labs, Inc. (US, Co-CEO: Jared Jonas, Colton Ottley, hereafter “Bend”) have agreed on Nitto’s acquisition of Bend.
June 1, 2022
·
2 min read
Nitto Strengthens Oligonucleotide Therapeutic Manufacturing Business
In response to the rapid market expansion of oligonucleotide therapeutics that have potential to treat both common and intractable diseases, Nitto Denko Corporation (Headquarters: Osaka; President: Hideo Takasaki; referred to hereafter as “Nitto”) will invest approximately 25 billion Japanese yen in Nitto Denko Avecia Inc.
March 31, 2021
·
3 min read
Business
New President Appointed for Nitto Avecia Inc.
Nitto Denko Avecia Inc. announced today that Detlef Rethage will step down from the position of President of Nitto Denko Avecia Inc., effective July 16, 2018.
August 3, 2018
·
2 min read
Business
n-Lorem Foundation Announces Partnership with Nitto Avecia to Strengthen Development of Personalized Medicines for Patients with Ultra-Rare Diseases
n-Lorem Foundation, a nonprofit organization that provides free, lifetime supplies of individualized RNA-targeted medicines to patients with ultra-rare diseases, today announced a new partnership with Nitto Avecia, the world’s largest oligonucleotide therapeutics manufacturer.
June 16, 2021
·
4 min read
Press Releases
Codexis’ Landmark Presentations at TIDES USA Highlight Reproducibility and Process Simplification of the ECO Synthesis Platform for Manufacturing siRNA
May 22, 2025
·
9 min read
Press Releases
FOXO TECHNOLOGIES INC. ANNOUNCES ACQUISITION AGREEMENT TO ACQUIRE VECTOR BIOSOURCE INC.
September 11, 2025
·
4 min read
Press Releases
KBI Biopharma, Inc. Announces Collaboration with Infinimmune Inc. to Support Antibody Manufacturing
September 9, 2025
·
3 min read
Press Releases
MEI Pharma, Inc. Rebrands as Lite Strategy, Inc., Adopts New NASDAQ Ticker ‘LITS’
September 11, 2025
·
4 min read
Genetown
Nitto Denko Avecia Inc. Announces Multiple Oligonucleotide Expansions
November 14, 2016
·
3 min read
Press Releases
genXtraits Inc. and Mendel Biotechnology, Inc. enter collaboration
August 21, 2025
·
3 min read
1 of 70,989
Next
